PEA improves the local control of disease with the resultant decrease in pulmonary artery pressure but may not influence the systemic inflammatory mechanisms in CTEPH patients through the RAGE pathway. The gene discussed is AGER; the disease is chronic thromboembolic pulmonary hypertension.